The drug ⬇️ the risk of ≥ 50% ⬇️ in eGFR or renal death in EMPEROR-Reduced (HR 0.51; 95% CI 0.33-0.79), but not in EMPEROR-Preserved (HR 0.95; 95% CI 0.73-1.24) #ESCCongress@ESC_Lavinia@escardio
#ESCCongress
HFpEF has recently been recognized 📌as the single greatest unmet need in CV Medicine
📌The landscape of HFpEF Tx is changing
📌Additional Studies are needed to confirm these results
Cluster 1 had higher LAV, LVEDV, and #LVESV, along with lower EF and less septal thickness, but slower EF and LVESV progression compared with Cluster 2.
Moderate SMR was more frequent in Cluster 1, whereas Cluster 2 had more non/trivial and mild #SMR
RV dysfunction as a predictor of clinical outcome in newly-Dx #HeartFailure
This analysis demonstrates #RVD at baseline and follow-up was associated with a higher risk of all-cause ☠️ [ HR- 1.66 (1.27-2.16) ] and HF 🏥 [ HR -2.20 (1.51-3.21) ]
Recovery of RV function is associated with better outcomes
This study also stated that improvement of TAPSE to ≥ 17mm during follow-up was associated with a reduction in all-cause ☠️ and #HeartFailure 🏥 (HR- 0.56[0.31-0.99] ), independent of
baseline TAPSE, age, sex, and LVEF
Using data from the #COAPT trial, a simple risk score using 4 clinical and 4 Echo parameters + 1 treatment-related variable (#TEER), which provides prognostic insight into the 2-year rates of ☠️ or #HeartFailure 🏥 in patients with symptomatic #HF and severe #FMR